Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.
Sci Transl Med. 2015 Mar 25;7(280):280sr1. doi: 10.1126/scitranslmed.3010274.
The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.
最近批准的两种药物能够阻断免疫检查点程序性细胞死亡蛋白 1（PD-1）的功能，这使得肿瘤免疫疗法牢固地确立在临床肿瘤学的主流地位。我们为这些最新进展提供了历史和免疫学背景，并讨论了转化研究，这些研究深入了解了癌症免疫疗法在个体患者水平上的疗效。
